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Quinolinic acid (QA) produces a pattern of selective cell loss in
the striatum, that closely mimics that of Huntington's disease (HD). The
aim of this study was to investigate the antioxidative status in the thala-
mus after intrastriatal application of QA and the influence of nerve
growth factor (NGF) on such neurotoxicity. Wistar rats were treated in-
trastriatally (coordinates: 8.4A, 2.6L, 4.8V), using a stereotaxic instru-
ment. The first group was treated with QA (150 nmol/l). The second
group was treated with QA, followed by NGF (4.5 g/kg b.w.). The con-
trol group was treated with 0.9 % saline solution. Seven days after the
treatment, we found decreased superoxide dismutase (SOD) activity in
mitochondrial fractions of the striatum of both groups. In the thalamus,
SOD activity showed no differences. The content of superoxide anion
increased in the striatum of QA- treated animals. It was decreased in
both structures in the group that was treated with QA and NGF. In the
QA+ NGF-treated group, we found increased glutathione peroxidase
(GSHPx) and GSH, compared to the group that was treated with QA
only, but these values were lower than in the controls. Thus, NGF
showed beneficial effects on the oxido-reduction status in the striatum,
and also in the thalamus, a structure that is separated from but tightly
connected with the striatum.
Key words: oxidative stress, NGF, rat, striatum, thalamus, quino-
linic acid
INTRODUCTION
Huntington's disease (HD) is a progressive neurodegenerative disorder
characterized by motor disturbance, cognitive loss and psychiatric manifesta-
tions. HD gene mutation seems to be widely expressed both in peripheral tissues
and in the central nervous system, but the fundamental biochemical mechanism,
which leads to neuronal degeneration, is unknown (Beal, 1995). Several tech-
niques have demonstrated abnormal metabolism in HD brain (Martin et al., 1992).
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There is a severe deficiency of respiratory chain enzyme system - complex II/ III
and a milder defect of complex IV (Harding, 1995).
The excitotoxic hypothesis of pathogenesis in Huntington's disease sug-
gests that selective striatal neuronal loss results from excessive activation of stri-
atal excitatory amino acid receptors. The neurotoxicity of 2,3 pyridinedicarboxylic
acid (quinolinic acid- QA) contributes to the pathogenesis of neuronal injury, such
as HD. QA is an endogenous excitotoxic metabolite of L-tryptophan, and it medi-
ates neuronal injury through N-methyl-D-aspartate (NMDA) receptor activation,
and subsequent elevation of intracellular calcium, oxidative stress and lipid per-
oxidation (Schwarcz et al., 1982). The predominant neuropathological feature of
HD is degeneration of the -aminobutyric acid (GABA)ergic, medium-sized spiny
neurons, which innervate the globus pallidus and substantia nigra pars reticulata
(Albin, 1995). These are critical parts of basal ganglia loop circuitry. The thalamus
is a structure which connects basal ganglia with appropriate parts of the neocor-
tex, and it has an important role in the motor and associative loops. The majority of
projections of striatum and nuclei, closely connected with it, converge through
the globus pallidus and thalamus to precentral parts of the cortex (area 4 and 6)
(Otake and Nakamura, 1998).
Besides its neurotrophic role in development, survival and recovery from in-
jury (Levi-Montalcini and Angeleti, 1968; Donald, 1995), it has been reported that
nerve growth factor (NGF) may be important in the detoxification of reactive oxy-
gen species (Park et al., 1998). It has been shown that intrastriatal implants of im-
mortalized central nervous system (CNS)- derived progenitor cells, that had been
genetically modified to secrete NGF, could prevent the neural degeneration in a
rodent model of HD (Kume et al., 1998).
NGF prevents degeneration of striatal neurons destined to die from excito-
toxic insult or mitochondrial dysfunction, so we decided to investigate the QA in-
duced changes in the antioxidative defence, as a consequence of its neurotoxic-
ity, in some parts of the basal ganglia loop (striatum and thalamus), and the influ-
ence of NGF on these effects of QA.
MATERIALS AND METHODS
Wistar rats of both sexes, weighing between 200 and 250 g, were used in the
experiments. The animals were housed inside a climate-controlled facility. Food
and water were available ad libitum. All animals received care in strict agreement
with good laboratory practice and in accordance with guidelines for the humane
care of animals, ethical principals of the Military Medical Academy and other fed-
eral statutes (Sl. list, 1998). The animals were anaesthetized with pentobarbital so-
dium i. p. in a dose of 40.5 mg/kg b.w. We used a stereotaxic instrument for small
animals for the administration of the substances in to the striatum (coordinates:
8.4A, 2.6L, 4.8V) (Paxinos and Watson, 1982). The substances were administered
using a Hamilton needle, and all of them were given in a volume of 10 l.
The animals were randomized into three groups. There were 8 animals in
each group. The first group of animals was treated with QA (Aldrich Chemical
Company, Inc, Milwaukee, USA), in the single dose of 250.7 g (150 nmol/l). The
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animals of the second group were treated with QA in the same dose, and after it,
they were treated with NGF (NGF- - Sigma, Aldrich Chemie, Germany), in a dose
of 4.5 g/ kg b.w. The control group was treated with 0.9 % sterile saline solution.
The animals were decapitated 7 days after the treatment and heads were
frozen immediately (-80oC). Prepared mitochondrial fractions of the striatum and
thalamus were used for the appropriate biochemical analyses (Lowry and Pas-
sonneau, 1974).
Superoxide dismutase (EC 1.15.1.1. SOD) activity was measured spectrop-
hotometrically, as inhibition of epinephrine autooxidation at 480 nm. The kinetics
were followed in sodium carbonate buffer (50 mM, pH -10.2; Serva, Feinbio-
chemica, Heidelberg, New York) containing 0.1 mM EDTA (Sigma, St. Louis,
USA), after addition of 10 mM epinephrine (Sigma, St. Louis, USA) (Suna and Zig-
man, 1978).
Superoxide anion content was determined through the reduction of nitro-
blue-tetrazolium (Merck, Darmstadt, Germany), in alkaline, nitrogen saturated
medium. Analysis was performed at 515 nm (Auclair and Voisin, 1985).
Glutathione peroxidase activity (EC 1.11.1.9; GSH-Px) was measured indi-
rectly, as oxidation of glutathione (GSH) to its oxidized form (GSSH), in the pres-
ence of a glutathione reductase (E.C. 1.6.4.2., Sigma, St. Louis, USA), at 340 nm.
The reaction was followed in potassium-phosphate buffer (50 mM pH-7.0; Serva,
Feinbiochemica, Heidelberg, New York), containing 1 mM EDTA (Sigma, St.
Louis, USA) (Maral et al., 1987).
The content of total glutathione (GSH + 1/2 GSSH) was determined with a
DTNB-GSSH reductase recycling assay. The rate of formation of 5-thio-2-nitro-
benzoic acid (TNBA), which is proportional to the total glutathione concentration,
was monitored spectrophotometrically at 412 nm (Anderson, 1986).
Descriptive data were expressed as the mean  standard error (SE). Statisti-
cal analysis was performed on a pentium PC, using a statistical software program
(Statistica 5.0 for Windows). Groups were compared by analysis of variance and
Students t-test. Differences were considered statistically significant at p<0.05.
RESULTS
After awakening, all rats from the group treated with QA, showed signs of hy-
perreactivity and convulsions. Neither animals of the second group (QA and
NGF), nor from the control one, showed any of these signs. Six hours after the op-
eration, the animals showed no behavioral differences, from the control ones.
We found decreased SOD activity in the ipsi and contralateral striatum in
both groups, compared to the control group. In the thalamus, we found no
changes in the SOD activity compared to the control group (Table 1).
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Table 1. Activity of SOD in the striatum and the thalamus in Wistar rats after an intrastriatal,
single dose of quinolinic acid (QA), given alone or in combination with nerve growth
factor (NGF). Values are given in U/mg protein. Mean ± SE.*- Significant difference in
comparison to corresponding values of the control group (p<0.05)
Group
Structure Control QA QA + NGF
Ipsilateral
striatum 800.24  127.67 625.44  73.63* 711.82  76.84*
Contralateral
striatum 726.30  43.28 615.33  36.03* 612.66  37.05*
Ipsilateral
thalamus 865.53  10.22 890.89  61.07 829.38  98.59
Contralateral
thalamus 835.14  63.61 850.13  34.73 833.18  43.77
The superoxide anion content was increased in the striatum, but was un-
changed in the thalamus, after QA administration, compared to the controls. It
was decreased after application of QA+NGF, compared to the QA - treated or
control group of animals (Figure 1).
GSHPx activity decreased in both structures, after application of QA, com-
pared to the control. After QA + NGF, GSHPx activity was increased, compared to
the group receiving QA only, but these activities were still less than for the controls
(Figure 2).
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Figure 1. Superanion content in the striatum and the thalamus in Wistar rats after intrastri-
atal single dose of QA, given alone or in combination with NGF. Values are given as
nmol NBT/mg proteins- mean  SE. * - Significantly different from corresponding val-
ues of the control group (p<0.05)
Superoxide anion
The content of total glutathione decreased in both structures and in both
groups, compared to the controls (Figure 3).
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Figure 3. GSH in the striatum and the thalamus in Wistar rats after intrastriatal single dose of
QA, given alone or in combination with NGF. Values are given as nmol/mg protein,
mean  SE.
* - Significantly different from corresponding values of control group (p<0.05)
Figure 2. GSHPx in the striatum and the thalamus in Wistar rats after application of QA and
in animals that were treated with NGF after QA. Values are given as mU/mg proteins-
mean  SE.




Excessive activation of glutamate receptors is known to induce an influx of
calcium ions into neurons, which entrains a destructive sequence of events within
the cell, leading to the generation of reactive oxygen species (Cohen, 1995; Mc
Donald and Johnston, 1990). These events initiate lipid peroxidation and disrup-
tion of membrane integrity, entry of calcium and a cellular energy crisis, that leads
to cell death (Flint Beal, 1994; Kehrer, 1993). Although the biochemical basis of
HD pathogenesis is not understood, several lines of evidence suggest that an ab-
normality of energy metabolism and compromised function of mitochondria can
be critical for the energy status (Richter and Kass, 1991). The proposed meha-
nism of destruction in our experiment, could be due to the excitotoxicity of QA,
and subsequent elevation of nitric oxide (NO) (Jelenkovic et al. 2002). It is well
known that NO has higher affinity for the superoxide anion than SOD for the dis-
mutation of this anion (Bredt and Snyder, 1994). Inability of a cell to maintain an
appropriate level of ATP, as the result of excitotoxicity, could activate metabolic
pathways involving arachidonic acid, which, besides well-known deleterious ef-
fects, could inhibit the return of glutamate from the synaptic space, and subse-
quently prolong action on the receptors (Murphy et al., 1989). The high potency of
QA in producing damage is the result of synergism between the activation of
NMDA receptors and the formation of free radicals.
The deficiency of glutathione that we have found, with resulting failure of de-
toxification of free radicals could increase the neurotoxic effects of glutamate
(Reed, 1990). Therefore, a low glutathione content might contribute to the excito-
toxic effects of glutamate in the striatum in HD. It was shown that soluble guanylat
cyclase activity is required for nerve cell death caused by glutathione depletion.
Cellular glutathione can be depleted by the release of the oxidized form, a process
which is accelerated under conditions of oxidative stress. Novel actions of GSH in
the nervous system have also been described, suggesting that GSH may serve
additionally both as a neuromodulator and as a neurotransmitter. GSH binds via
its gamma- glutamyl moiety to ionotropic receptor. At micromolar concentrations
GSH displaces excitatory agonists, acting to halt their physiological actions on
target neurons. At millimolar concentrations, GSH, acting through its cysteinyl
thiol group, modulates the redox site of NMDA receptors. As such modulation has
been shown to increase NMDA receptor channel currents, this action may play a
significant role in normal and abnormal synaptic activity. GSH in the nanomolar to
micromolar range binds to at least two populations of binding sites that appear to
be distinct from all known excitatory amino acid receptor subtypes. GSH bound to
these sites is not displaceable by glutamatergic agonists and antagonists. These
binding sites, which are distinct receptor populations, appear to recognize the
cysteinyl moiety of the GSH molecule. Like NMDA receptors, the binding sites
possess a coagonist site(s) for allosteric modulation. GSH may be involved both
directly or indirectly in synaptic transmission (Janaky et al, 1999). Methods to in-
crease endogenous glutathione levels in neurodegenerative diseases associated
with oxidative stress may be promising.
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GSHPx is a critical intracellular enzyme involved in detoxification of hydro-
gen peroxide (H2O2) to water. In our experiment, decreased GSHPx activity after
application of NGF could be due to decreased superoxide anion content, and
subsequent decreased production of H2O2. It has been found that knock- out of
GSHPx may be adequately compensated under nonstressed conditions, but, af-
ter administration of mitochondrial toxins, GSHPx plays an important role in de-
toxifying oxygen radicals (Smith et al, 1996). GSHPx coupled to reduce nicotine
adenine diphosphate regenerating systems via glutathione reductase is virtually
able to guarantee effective protection of biological structures against oxidative at-
tack (Kliveny et al., 2000).
There are many contradictory references about the influence of neurotro-
phins on the mechanism of excitotoxicity (Shen et al., 1997). It is known that NGF
has some influence on some components of the antioxidant system, particularly
the metabolism of glutathione. There is some evidence for a stimulative effect of
NGF on the activity of -glutamyl-cysteine-sythetase (-GC-S), GSHPx and glu-
cose-6-phosphate dehydrogenase (Pan and Perez-Polo, 1993; Pan and Perez-
Polo 1996). NGF-tg mice showed a better response to oxidative stress, because of
increased basal activity of Cu-Zn SOD and glutathione transferase (Guegan et al.,
1999). Besides the changes in oxido-reduction status, NGF can alter the expres-
sion of glutamatergic receptors and that might be the beginning of the "dark side"
of neurotrophic action (Behrens, 1999). There is some evidence for synergistic ac-
tion of NGF and NO, which can partly explain the protective efect of this neurotro-
phin in our experiment. It has been found that NGF may operate via NO activity. It
is known that NGF in PC12 and cultured basal forebrain cells increases the ex-
pression of neural NOS gene (Holzman et al., 1996) Also, NO can modulate the re-
lease of neurotransmitters and has an influence on nerve growth (Phung et al.,
1999).
There is some evidence for connected metabolic pathways of tryptophan
and its metabolites and NGF. Thus, L-Kynurenine, markedly increases the level of
mRNAs for NGF. Other tryptophan metabolites, such as QA, kynurenic acid and
serotonin had little effect on the levels of NGF mRNA (Dong- Rual et al., 1998).
The beneficial effect of NGF in the thalamus could be caused by retrograde
axonal transport (Hendry and Hill, 1980). Despite the beneficial behavioral effect
of NGF in our investigations, we have found partly damaged antioxidative defence
in the striatum, and also, in the thalamus, which was distinct from the place of ap-
plication. The thalamus is very tightly anatomico - functionally connected to the
striatum, so the excitotoxic effect of QA probably spread. Decreased GSHPx and
total glutathione content, could be indicators for some other mechanism of NGF
protection, not only antioxidative.
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EFEKAT NGF NA ANTIOKSIDATIVNU ODBRANU U TALAMUSU PACOVA NAKON
NEUROTOKSI^NOG DELOVANJA HINOLINSKE KISELINE
NINKOVI] MILICA, JOVANOVI] MARINA, MALI^EVI] @, JELENKOVI] ANKICA, \UKI] MIRJANA i
VASILJEVI] IVANA
SADR@AJ
Hinolinska kiselina (HK) prouzrokuje takav selektivni gubitak }elija u strija-
tumu, koji veoma dobro imitira onaj kod Huntingtonove bolesti. Cilj ovog istra`i-
vanja bio je da se ispita antioksidativni status u talamusu nakon aplikacije HK u
strijatum i uticaj NGF na takvu neurotoksi~nost. Wistar pacovi su tretirani intrastri-
jatno, pomo}u stereotaksi~nog instrumenta (koordinate: 8,4A, 2,6L, 4,8V). Prva
grupa je bila tretirana HK (150 nmol/l). Druga grupa je bila tretirana HK, a nakon
toga je dobila NGF (4.5 g/ kg b.w.). Kontrolna grupa je bila tretirana fiziolo{kim
rastvorom. Sedam dana nakon tretmana, u mitohondrijskim frakcijama strijatuma,
na{li smo smanjenu aktivnost SOD u obema grupama. U talamusu, aktivnost
SOD se nije promenila. Sadr`aj superoksidnog anjona se pove}ao u strijatumu
`ivotinja koje su bile tretirane HK, a smanjio se u obema strukturama, u grupi koja
je bila tretirana sa HK i NGF. U HK+ NGF-tretiranoj grupi, na{li smo pove}anu
aktivnost GSHPx i GSH u odnosu na grupu koja je bila tretirana samo sa HK, ali su
te vrednosti bile manje u odnosu na kontrolne. NGF je pokazao povoljne efekte na
oksido-reduktivni status u strijatumu, ali tako|e i u talamusu, strukturi koja je
odvojena, ali veoma blisko povezana sa strijatumom.
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